Melanoma experts from the National Comprehensive Cancer Network (NCCN) consider targeted ICIs (aPD-1, aCTLA-4) to be more effective and better tolerated than IFN-α and therefore no longer recommend it for the adjuvant treatment of cutaneous melanoma [145]. This evidence concerns the gene IFNA2 and melanoma.